Table 5 Trials of WBRT plus radiation sensitizers for brain metastases
From: Neuropsychological testing and biomarkers in the management of brain metastases
Study (ref) | Year | n | Radioenhancer | (Gy)/number of fractions | Median Survival (months) WBRT + RS vs WBRT |
|---|---|---|---|---|---|
Eyre et al. [31] | 1984 | 111 | metronidazole | 30/10 | 3.0 vs 3.5 |
DeAngelis et al. [32] | 1989 | 58 | lonidamine | 30/10 | 3.9 vs 5.4 |
Komarnicky et al. [33] | 1991 | 779 | misonidazole | 30/6-10 | 3.9 |
Phillips et al. [34] | 1995 | 72 | BUdR | 37.5/15 | 4.3 vs 6.1 |
Mehta et al. [35] | 2003 | 401 | motexafin gadolinium | 30/20 | 5.2 vs 4.9 |
Shaw et al. [30] | 2003 | 57 | efaproxiral | 30/10 | 7.3 vs 3.4 |
Suh et al. [36] | 2006 | 515 | efaproxiral | 30/10 | 5.4 vs 4.4 |
Knisely et al. [37] | 2008 | 183 | thalidomide | 37.5/15 | 3.9 vs 3.9 |